These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 22585977)

  • 1. Q&A: Alan Auerbach on small and speedy biotechs. Interview by Eric Bender.
    Auerbach A
    Cancer Discov; 2012 Mar; 2(3):198. PubMed ID: 22585977
    [No Abstract]   [Full Text] [Related]  

  • 2. Small biotechs raring to cash in on the orphan disease market.
    Hersher R
    Nat Med; 2012 Mar; 18(3):330-1. PubMed ID: 22395682
    [No Abstract]   [Full Text] [Related]  

  • 3. Biotech entrepreneurs swoon over proposed fundraising changes.
    Venkataramanan M
    Nat Med; 2012 Jan; 18(1):3. PubMed ID: 22227645
    [No Abstract]   [Full Text] [Related]  

  • 4. Biotechs recoil at hedge fund manager's patent attacks.
    Senior M
    Nat Biotechnol; 2015 Jul; 33(7):680-1. PubMed ID: 26153996
    [No Abstract]   [Full Text] [Related]  

  • 5. Biotech patents-business as usual?
    Lawrence S
    Nat Biotechnol; 2008 Dec; 26(12):1326. PubMed ID: 19060861
    [No Abstract]   [Full Text] [Related]  

  • 6. Billion dollar babies--biotech drugs as blockbusters.
    Lawrence S
    Nat Biotechnol; 2007 Apr; 25(4):380-2. PubMed ID: 17420735
    [No Abstract]   [Full Text] [Related]  

  • 7. More than meets the eyes?
    Jacobs T
    Nat Biotechnol; 2004 Oct; 22(10):1221. PubMed ID: 15470455
    [No Abstract]   [Full Text] [Related]  

  • 8. Biotech drug market steadily expands.
    Lawrence S
    Nat Biotechnol; 2005 Dec; 23(12):1466. PubMed ID: 16333279
    [No Abstract]   [Full Text] [Related]  

  • 9. Bugs or drugs, tortoises or hares?
    Jacobs T
    Nat Biotechnol; 2005 Mar; 23(3):293. PubMed ID: 15765079
    [No Abstract]   [Full Text] [Related]  

  • 10. Deconstructing Myogen's market cap.
    Ransom J
    Nat Biotechnol; 2006 Mar; 24(3):227-8. PubMed ID: 16525363
    [No Abstract]   [Full Text] [Related]  

  • 11. Biotechnology partnerships--medicine for an ailing industry?
    DeLamarter J
    Nat Biotechnol; 2003 Aug; 21(8):847-8. PubMed ID: 12894192
    [No Abstract]   [Full Text] [Related]  

  • 12. The 802 million dollars fallacy.
    Hodgson J
    Nat Biotechnol; 2004 Sep; 22(9):1076. PubMed ID: 15340464
    [No Abstract]   [Full Text] [Related]  

  • 13. What's fueling the biotech engine?
    Aggarwal S
    Nat Biotechnol; 2007 Oct; 25(10):1097-104. PubMed ID: 17921989
    [No Abstract]   [Full Text] [Related]  

  • 14. Auctioning the cure.
    Willyard C
    Nat Med; 2011 May; 17(5):528-30. PubMed ID: 21546960
    [No Abstract]   [Full Text] [Related]  

  • 15. The quiet revolution.
    Nat Biotechnol; 2003 Jul; 21(7):715. PubMed ID: 12833072
    [No Abstract]   [Full Text] [Related]  

  • 16. Putting your best mode forward.
    Tsao YR; Tabtiang RK
    Nat Biotechnol; 2000 Oct; 18(10):1113-4. PubMed ID: 11017054
    [No Abstract]   [Full Text] [Related]  

  • 17. Back on target.
    Webb S
    Nat Biotechnol; 2013 Mar; 31(3):191-3. PubMed ID: 23471062
    [No Abstract]   [Full Text] [Related]  

  • 18. What's fueling the biotech engine-2007.
    Aggarwal S
    Nat Biotechnol; 2008 Nov; 26(11):1227-33. PubMed ID: 18997759
    [No Abstract]   [Full Text] [Related]  

  • 19. Public biotech 2009-the numbers.
    Huggett B; Hodgson J; Lähteenmäki R
    Nat Biotechnol; 2010 Aug; 28(8):793-9. PubMed ID: 20697401
    [No Abstract]   [Full Text] [Related]  

  • 20. Biotechs hedge against big pharma givebacks.
    Dorey E
    Nat Biotechnol; 1999 May; 17(5):416-7. PubMed ID: 10331784
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.